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Giant condyloma acuminatum or Buschke-Lowenstein tumour is a very rare disease which usually is located in the genital,
anorectal, and perianal regions. It is regarded as a type of verrucous carcinoma occurring on anogenital mucosal surfaces where it
is locally invasive but displays a benign cytology. We describe a case of a 24-year-old woman with persisting condyloma acuminata
progressing to a large intra-abdominal Buschke-Lowenstein tumour. To our knowledge such an advanced stage has only been
reported once before. The severity and extent of the tumour both determine the treatment and patient outcome. Treatment was
impeded by cachexia, an immunosuppressive state after kidney transplantation and difficulties in establishing a reliable diagnose.
Interferon treatment was started which initially led to tumour reduction but was complicated by an interferon-induced pancreatitis,
pneumonia, and fasciitis necroticans resulting in death. We present a literature overview on the treatment options for a Buschke-
Lowenstein tumour, with emphasis on interferon therapy, with all the advantages and disadvantages.
1. Introduction
Worldwide prevalence of human papilloma virus (HPV) is
10%,mostly affectingwomenunder the age of 35 [1].The asso-
ciated condylomata acuminata (CA) has an estimated preva-
lence of 0.75–3% in Europe and 1% in the United States [2].
One of the risk factors for CA is an immune-compromised
state. On rare occasions progression to a Buschke-Lowenstein
tumour (BLT) occurs. A BLT is a very rare, slowly growing,
locally destructive, and infiltrative tumour associated with
HPV types 6, 11, 16, and 18. Usually the tumour is located
in the genital, anorectal, and perianal regions. Despite the
benign histological characteristics of the tumour there is a
high risk of recurrence and malignant transformation to
squamous cell carcinoma (SCC), in particular for HPV types
16 and 18 [3–7]. Little is known about the true incidence rates
of BLT due to the difficulties in histomorphological differ-
entiation and thereby making the correct diagnosis. Current
literature reports an increase to 6.3 cases per year in the last
decade [8]. Due to this low incidence little is known about
treatment outcomes, making comparison between various
treatment regimens difficult.
To date only three papers are available reporting on,
respectively, 42, 63, and 51 cases [3, 8, 9] and one small review
[10]. They conclude that complete resection is the preferred
initial therapy as it has the highest success rate and the lowest
risk of recurrence. Contradictory is that surgery can be very
mutilating as extensive resection is usually required due to
ingrowth into local structures. Alternatively chemotherapy
and radiation therapy have been described with varying
results. However, in most cases, it proved to be difficult to
determine a true malignancy so that there is a risk of over-
treatment.
A possible alternative treatment may be interferon ther-
apy as an effort to boost the patient’s own immune system [1–
16]. As a new and experimental treatment for targeting BLT,
there are no large series available let alone randomized trials.
The majority of available data comes from other case reports
and small case series concerning CA [17–20]. We present a
rare case and provide a literature overview on the treatment
options for a BLT, with emphasis on interferon therapy.
2. Case Presentation
A24-year-old cachectic female patient, with a status after kid-
ney transplantation due to hemolytic-uremic syndrome in
2000, was referred to our university medical center because
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of persisting incapacitating CA under prolonged immuno-
suppressive therapy. Her initial immunosuppression regimen
consisted of tacrolimus 5mg and prednisolone 7.5mg daily.
At presentation in 2010 she suffered from severe CA located
both intravaginal and perianal (Figure 1). This has led to
excessive pain and defecation problems despite local and
topical treatment by surgeons, gynaecologists, and dermatol-
ogists for over five years. Viral serology revealed the patient to
beHPV-16 andHPV-18 positive.HerHIV statuswas negative.
At our center multiple biopsies revealed serious dysplasia,
and only one sample revealed malignant cells. Because of
persistent lower back pain a MRI scan was performed. This
showed a large process in the lower pelvic region with
extension into the abdomen and cavum douglasi, consistent
with the diagnosis intra-abdominally located BLT (Figure 2).
Prior to presentation at our hospital, the patient already
had, in vain, several surgical procedures to obtain local
control. At presentation both the cachexia of the patient, the
localisation and infiltration of the process made surgical
treatment (anterior and posterior exenteration) no realistic
option. As a malignancy could not be definitely established,
radio- or chemotherapy was therefore not indicative. Because
the tumour had centrally liquefied, resulting into abscesses,
multiple drainage procedures were necessary. In order to
treat the BLT the immunosuppressive therapy was lowered
to 5mg prednisone daily, and interferon therapy was started
as an effort to boost the patients’ immune system [12, 15, 16].
After multidisciplinary consultation a dosage of 180 𝜇g/week
interferon alfa 2B was given by subcutaneous injections.
After it became clear that the kidney function remained
stable, the immunosuppressive therapy was further lowered
to 5 and 2.5mg prednisolone every other day. Because of
severe malnutrition and cachexia, the patient received gastric
tube feeding. During the interferon therapy a new abscess
arose in the lower back, which was found to have a direct
relationship with the BLT. On a follow-up MRI and CT scan,
respectively, two and four months after the first interferon
injection, a reduction in tumourmass was visible. As a chance
finding an interferon-induced pancreatitis was visible on
the CT. There were no further adverse effects of the ther-
apy. Based on the established tumour reduction, interferon
therapy was continued. Unfortunately after four months of
treatment the patient was readmitted to our hospital because
of a pneumococcal pneumonia for which antibiotic therapy
was started. During hospitalization the patient developed
progressive pain in the lower back and left leg in combination
with a septic profile. The diagnosis necrotizing fasciitis was
made and due to the clinical condition of the patient,
combined with the extent of the disease, the treatment was
discontinued in agreement with the family and the patient
died. Unfortunately no informed consent was obtained for a
postmortem examination.
3. Discussion
This report underlines the impact and difficulties of treating
BLT. Progression to an intra-abdominal mass even further
complicates treatment and to date has been described only
once. Early detection of abdominal involvement in combina-
tion with a reliable histopathological diagnosis is essential for





Figure 2: MRI scan of the small pelvic. A mass, originating
from the perianal region, is expanding along the endopelvic fascia
to dorsolateral with ingrowth in the left m. obturatoria and m.
piriformis and ventral in the m. gluteus (Capitol A). No bladder
ingrowth visible (Capitol B). The mass does have a direct relation
with the wall of the lower rectum (Capitol C).
determining the appropriate treatment and predicting treat-
ment outcome. When confronted with possible BLT it is very
important to exclude an underlyingmalignancy. Other pelvic
malignancies (gynaecological, gastrointestinal, and urologi-
cal) should be considered, especially in younger women and
patients with HPV types 16 and/or 18. In transplantation
patients, posttransplant lymphoproliferative disorder should
also be excluded, which was done in this patient and turned
negative. In large BLTs possible sampling errors can make
reliable detection of amalignancy difficult as they can contain
malignant, premalignant, and/or benign cells. Also in our
case only one biopsy sample revealed malignant cells. Repet-
itive biopsies were never able to definitely demonstrate true
malignant transformation.
This report also shows that the choice of treatment is
highly dependent on patient factors, such as cachexia and
immune state in our patient. In this case abdominal involve-
ment became apparent in an already advanced stage. With
this paper we hope to createmore awareness for the complex-
ity of this disease and the considerations that must be taken.
A BLT is a rare condition, and, although the incidence
appears to be increasing, there remains a lack of evidence on
the appropriate steps to take in the treatment of these patients
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[8]. The tumour has a considerable risk of malignant trans-
formation into fully invasive SCC or verrucous carcinomas
[1, 7]. The disease is thereby associated with high recurrence
and mortality rates of, respectively, 67 and 21 percent [3].
One of the main risk factors for the development of a BLT is
an immune-compromised state. The cell-mediated immune
response is essential in the natural control of HPV infections
[12, 22]. Immunosuppressive drugs increase the risk of post-
transplant cancer. Inparticular cyclosporines reduce UV-
induced DNA repair by peripheral blood mononuclear cells
[23, 24]. Without prompt and adequate treatment of a BLT
there is a risk of local invasiveness leading to various com-
plications such as abscess formation, fistulas, and defecation
problems by ingrowth in or pressure to the rectum [3, 9].
In current literature only one case has been described with
a similar intra-abdominal mass as in our patient. In this
particular case extend of the disease was only detected during
surgery [25]. In order to avoid this it has been suggested to
perform a CT scan prior to surgery to be properly informed
on the extent of the disease [26]. In this case the scan proved
to be of great value.
When treatment is considered, the first choice is surgery
in which a radical resection should be achieved [3, 5, 8, 9].
Despite radical or wide local excision the tumour still has a
high recurrence rate of 50% [3]. The possibilities for surgery,
however, are sometimes limited by factors as a poor baseline
condition and advanced disease due to patient or doctors
delay [10–13, 16]. Surgical therapy often requires extensive
resections by means of anterior and posterior exenteration or
even a pelvectomy [12, 27].
Chemo- and/or radiotherapy have been applied in many
different ways, usually following unsuccessful surgical treat-
ments. If an underlyingmalignancy can be established, radio-
and/or chemotherapy as main treatment or prior to surgery
[27–32] seem to have good results [9]. However, when used
after multiple surgical interventions or as adjuvant therapy,
results are less favorable [3, 33]. The detection or exclusion of
malignant transformation is essential before initiating ther-
apy but can be very difficult to obtain. In an early stage of the
disease sampling error can easily occur. Representative bio-
psies herein can be decisive in the establishment of a malig-
nancy [12, 34]. Only one report showed good results with
chemoradiation as adjuvant therapy prior to surgery without
first verifying amalignancy [25].This is however a rather con-
troversial approach and can therefore not be recommended as
initial treatment.
Another controversial alternative to surgery or radio-
chemotherapy is the administration of interferon. Interferon
has been described as a treatment for CA andBLTwhen other
treatments have been excluded or unsuccessful. The pub-
lished results with this treatment are very contradictory and
vary from a complete lack of effect [10, 11, 13, 14, 17] to a reduc-
tion of the disease [12, 15, 16, 19, 35]. A recent meta-analysis
unfortunately showed no superior effect of imiquimod (inter-
feron𝛼) compared to podophyllotoxin in the treatment of CA
[20]. Only few side effects of interferon are described in lit-
erature varying from miscellaneous reactions as fever, chills,
headache, myalgia’s, and leucocytosis to more severe and life
threatening side effects as pericarditis, autoimmune disease
and myelosuppression [16, 17, 19, 36–38]. When considering
treatment with interferon there is a lack of consensus in
dosage, frequency, and length of treatment (Table 1) [10–
16, 21]. We encountered the same problem and after exten-
sive multidisciplinary consultation decided to a dosage of
180 𝜇g/week interferon alfa 2B by subcutaneous injections.
As tumour reduction had been established during follow-up
CT, an appropriate dose-effect relationshipwas assumed.Due
to the short follow-up this cannot be determined with any
certainty.
This case has a few shortcomings. As mentioned in the
introduction, surgery is considered first-choice treatment.
Unfortunately at the time of presentation at our hospital the
BLT had already grown into adjacent structures. Whether
extensive resection or debulking still would have had a pos-
itive outcome cannot be assessed. Another consideration
could have been to suspend all immune suppressant therapy
instead of just lowering the dosage. Ceasing the prednisolone
could possibly have led to a better effect of the interferon
therapy and prevented the fasciitis. Furthermore, immuno-
suppressant drugs such as sirolimuswere not considered.This
could have had a positive contribution because it has antipro-
liferative properties. Also, considering the high costs of inter-
feron therapy, the lack of consensus on the appropriate form
of administration and dosage, and the potentially serious side
effect, this certainly cannot be recommended as standard
therapy.
In conclusion, we report one of the first cases of a large
intra-abdominally located BLT. We have tried to provide
a practical overview of current treatment options, which
may benefit future patients. The outcome of each treatment
depends on the disease stage, differentiation, and patient
characteristics. Although in this case surgery was no longer
a realistic option it should be considered the gold standard.
Interferon therapy is a costly and still experimental treatment
and should be regarded as a last resort. Patients should be very
thoroughly informed about the potential life-threatening
risks.
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